These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 6389807)
21. The role of aluminum in renal osteodystrophy. Sherrard DJ Mayo Clin Proc; 1993 May; 68(5):510-1. PubMed ID: 7683073 [No Abstract] [Full Text] [Related]
23. The use of desferrioximine in dialysis-associated aluminium disease. Ackrill P; Day JP Contrib Nephrol; 1993; 102():125-34. PubMed ID: 8416177 [No Abstract] [Full Text] [Related]
24. Role of plasma aluminum in the detection and prevention of aluminum toxicity. Winney RJ; Cowie JF; Robson JS Kidney Int Suppl; 1986 Feb; 18():S91-5. PubMed ID: 3458005 [No Abstract] [Full Text] [Related]
25. Aluminum: culprit or accessory in the genesis of renal osteodystrophy. Quarles LD; Gitelman HJ; Drezner MK Semin Nephrol; 1986 Mar; 6(1):90-101. PubMed ID: 3299578 [No Abstract] [Full Text] [Related]
26. [Myopathies in chronic renal failure patients on dialysis]. Henning HV Dtsch Med Wochenschr; 1996 Jan; 121(4):115. PubMed ID: 8631240 [No Abstract] [Full Text] [Related]
27. [Chronic aluminum intoxication in patients with terminal kidney failure on programmed hemodialysis (literature review)]. Milovanova LIu; Nikolaev AIu; Barashkov GK Ter Arkh; 2001; 73(6):67-9. PubMed ID: 11521528 [No Abstract] [Full Text] [Related]
29. [Role of aluminum in osteodystrophy and anemia in chronic renal failure]. Cannata Andía JB An Med Interna; 1991 Jun; 8 Suppl 2():21. PubMed ID: 1878466 [No Abstract] [Full Text] [Related]
30. [Prevention and treatment of renal osteodystrophy: present and future]. Fernández E; Craver L Nefrologia; 2006; 26 Suppl 3():19-27. PubMed ID: 17469423 [No Abstract] [Full Text] [Related]
31. Epidemiology of aluminium toxicity in a 'low incidence' area. Winney RJ; Cowie JF; Cumming AD; Short AI; Smith GD; Robson JS Contrib Nephrol; 1984; 38():47-58. PubMed ID: 6713900 [No Abstract] [Full Text] [Related]
32. Prophylaxis and methods for early recognition of aluminium intoxication. Fuchs C; Armstrong VW; Quellhorst E; Scheler F Contrib Nephrol; 1984; 38():81-94. PubMed ID: 6713903 [No Abstract] [Full Text] [Related]
33. [Effects of aluminum gels on renal osteodystrophy caused by chronic hemodialysis. Increase in the total surface of osseous resorption in anephric patients]. Fournier A; Tunchot S; Bedrossians J; Idatte JM; Bordier P Sem Hop; 1974 Nov; 50(45):2803-10. PubMed ID: 4375854 [No Abstract] [Full Text] [Related]
34. [Role of aluminium and magnesium effects on initiation and promotion of renal osteodystrophy in patients with chronic renal failure]. Nakamrua M; Sato N; Tsukamoto Y; Marumo F; Iwanami S Nihon Jinzo Gakkai Shi; 1986 Apr; 28(4):421-8. PubMed ID: 3747253 [No Abstract] [Full Text] [Related]
35. Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH. Nebeker HG; Andress DL; Milliner DS; Ott SM; Alfrey AC; Slatopolsky EA; Sherrard DJ; Coburn JW Kidney Int Suppl; 1986 Feb; 18():S96-9. PubMed ID: 3458006 [No Abstract] [Full Text] [Related]
36. Aluminum toxicity from oral sucralfate therapy. Burgess E Nephron; 1991; 59(3):523-4. PubMed ID: 1758558 [No Abstract] [Full Text] [Related]
37. Aluminum and renal osteodystrophy in chronic uremia. Berland Y; Grandvuillemin M; Charhon S; Olmer M Kidney Int Suppl; 1985 Dec; 17():S183-7. PubMed ID: 3867793 [No Abstract] [Full Text] [Related]
38. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553 [TBL] [Abstract][Full Text] [Related]
39. Clinical features of aluminum-associated bone disease in long-term hemodialysis patients. Iwamoto N; Ono T; Yamazaki S; Fukuda T; Kondo M; Yamamoto N; Hiratake Y; Masugi Y; Kubo Y; Hino M Nephron; 1986; 42(3):204-9. PubMed ID: 3945360 [TBL] [Abstract][Full Text] [Related]